JNJ
$268.73+0.91%
as of close, Oct 27, 2026
☾ AH $268.73 +0.91%
JNJ — Johnson & Johnson price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDE
120.0140.0160.0180.0200.0220.0240.0260.00200.0M400.0M$268.73—20162019202120242026
2026-10-27
Price$268.73
MA20$254.36
MA50$229.13
Vol27.0M
Key stats#
Price data
- Price
- $268.73
- YTD price return
- +29.85%
- YTD total return
- +31.94%
- Market cap
- 646.9B
- Enterprise value
- 675.7B
- Shares outstanding
- 2.4B
- 52W low
- $184.66
- 52W high
- $281.07
- From 52W high
- -4.39%
- From 52W low
- +45.53%
- 52W range
- 87%
- Beta
- 0.24
Volume
- Rel volume
- 0.77×
- 30D volume
- 7.5M
- 30D $ vol
- 2B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$62.0M
- Insider net 1Y
- −$150.7M
Form 4 transactions by trade date, as filed; latest on file 2026-09-02.
Fundamentals
- Sales (ttm)
- 99.3B
- Sales/share
- $41.26
- EPS (ttm)
- $6.58
- FCF (ttm)
- 20.6B
- FCF/share
- $8.55
- Book value/share
- $33.87
- Net margin
- 16.20%
- ROE
- 19.74%
- ROA
- 8.15%
- Debt / equity
- 0.44×
- Current ratio
- 1.02
Growth (CAGR, ttm) · 10Y
- Sales
- +7.83%+5.89%+1.67%+3.38%
- Net income
- -36.02%-22.60%-2.09%+0.10%
- FCF
- +5.08%+9.41%-1.73%+4.16%
- Shares
- -0.08%+0.00%-1.78%-1.22%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -36.53%-21.29%-0.32%+1.46%
- Sales/share
- +7.92%+5.89%+3.52%+4.66%
- FCF/share
- +5.17%+9.41%+0.05%+5.45%
- Book value/share
- +2.94%+4.62%+4.89%+2.39%
- Dividend/share
- +3.95%+4.42%+5.00%+5.48%
- Price
- +41.25%+22.66%+10.42%+8.90%
- Total return
- +44.43%+26.19%+13.55%+11.90%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 40.8×
- Fwd P/E
- 22.7×
- P/S (ttm)
- 6.5×
- P/B (mrq)
- 7.9×
- P/FCF (ttm)
- 31.4×
- EV/EBITDA (fy)
- 25.2×
- EV/Sales (ttm)
- 6.8×
- FCF yield (ttm)
- 3.18%
- Dividend yield (fwd)
- 1.99%
- Dividend yield (ttm)
- 1.96%
- Dividend/share (fwd)
- $5.36
- Buyback yield (realized, 1y)
- 0.08%
- Shareholder yield (realized, 1y)
- 3.02%
- Buyback yield (cash, ttm)
- 1.22%
- Shareholder yield (cash, ttm)
- 3.18%
Vs own 10Y history
- P/E
- 90th
- P/S
- 97th
- P/B
- 100th
- P/FCF
- 99th
Bar = where today’s multiple sits in JNJ’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+0.91%
5D
+3.61%
1M
-0.92%
3M
+1.05%
YTD
+29.85%
1Y
+41.21%
5Y
+64.12%
Recent filings#
- Oct 13Earnings · Earnings release — EPS $2.59 vs $2.53 est. (+2.4%); revenue $25.40B (+6% y/y) 5.7%
- Sep 2Insider sale · Schmid Timothy (EVP, WW Chair, MedTech) sold 33,597 shares for $9.2M at $274.74
- Aug 17Insider sale · Taubert Jennifer L (EVP, WWC. Innovative Medicine) sold 15,000 shares for $4.0M at $263.36
- Aug 13Insider sale · Duato Joaquin (CEO and Chairman of the Board · Director) sold 171,771 shares for $44.7M on 2 days since Aug 5
- Aug 6Insider sale · Forminard Elizabeth (EVP, Chief Legal Officer) sold 15,918 shares for $4.1M at $255.93–$257.76
Financial statements
Open full JNJ financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
| GILD | Gilead Sciences Inc. | +5.40% | +0.25% |
